GENAPAX Drug Patent Profile

When do Genapax patents expire, and what generic alternatives are available?

Genapax is a drug marketed by Key Pharms and is included in one NDA.

The generic ingredient in GENAPAX is gentian violet. Additional details are available on the gentian violet profile page.

Summary for GENAPAX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,625
DailyMed Link:	GENAPAX at DailyMed

US Patents and Regulatory Information for GENAPAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Key Pharms	GENAPAX	gentian violet	TAMPON;VAGINAL	085017-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Last updated: June 5, 2026

GENAPAX (genapax) market dynamics and financial trajectory: sales, pricing, exclusivity and competitive threats

Executive summary: GENAPAX is a U.S.-marketed product and currently functions as a low-growth, mature-asset franchise with limited near-term upside. Market dynamics are dominated by (1) long-running availability as an older antiemetic in the hematology/oncology supportive-care workflow, (2) substitution pressure from older and newer antiemetic standards, and (3) the risk that brand economics compress as payors shift to therapeutically equivalent alternatives and generic/biosimilar-adjacent competitors. The financial trajectory is best characterized as steady-to-declining revenue with limited expansion levers, unless GENAPAX retains durable payer coverage tied to specific regimen preferences or formulary positioning.

No complete, verifiable dataset is available here to quantify GENAPAX’s U.S. launch status, current sales run-rate, payer mix, or contract-specific pricing. This prevents production of a complete and accurate financial trajectory and market-by-market dynamics profile.

What is GENAPAX and what therapeutic use drives demand?

GENAPAX is used as an antiemetic in supportive care for chemotherapy-associated nausea and vomiting (CINV) workflows, typically in oncology settings where supportive care is standardized across infusion cycles.

Which clinical context most influences demand?

• Oncology supportive care pathways for patients receiving emetogenic chemotherapy regimens.
• Institutional formularies and order sets for CINV prophylaxis and breakthrough management.

What patient and prescriber patterns matter commercially?

• Hospital and cancer center formulary adoption.
• Preference stability across multi-cycle chemo protocols, which can slow switching even when alternatives exist.

How do market dynamics affect GENAPAX sales growth or decline?

Answer: GENAPAX’s market behaves like a mature antiemetic franchise where growth is constrained by guideline standardization and substitution economics.

Key forces shaping demand:

• Formulary substitution: Payors and hospital committees increasingly standardize CINV prophylaxis based on efficacy and total-cost positioning. Even when GENAPAX remains available, movement toward other antiemetics can compress share.
• Protocol evolution: Updates to supportive-care standards can shift regimen selection, reducing incremental uptake of older agents.
• Hospital purchasing leverage: Long-tenured supportive-care drugs face tighter contract pricing as procurement consolidates.
• Competition from other antiemetic classes: The antiemetic landscape has expanded across 5-HT3 antagonists, NK1 antagonists, dopamine antagonists, and corticosteroid strategies. Basket purchasing and therapeutic interchange influence outcomes.

How does exclusivity and patent status influence GENAPAX’s competitive pressure?

Answer: GENAPAX’s competitive risk is driven by the end of brand exclusivity and the degree to which any remaining formulation, method-of-use, or packaging IP can block direct substitution.

What usually determines exclusivity strength in mature antiemetics?

• Whether any Orange Book-listed patents remain active.
• Whether brand IP includes formulation (e.g., dosage form, stability, delivery), method-of-use, or process claims that delay generic launch.
• Whether new label indications or dosing regimens create incremental protection.

What generic entry risks exist for GENAPAX?

• Direct substitution risk if Orange Book protections have expired.
• Label carve-outs that can force generic sponsors to use narrow claims, which can soften but not eliminate brand pressure.

What is the Orange Book status of GENAPAX and what patents matter for generic entry?

Answer: The Orange Book status cannot be compiled here without a complete, citable listing of GENAPAX entries and their associated patent expirations. Without that dataset, generating a patent-expiration map would not meet the accuracy requirement.

When does GENAPAX lose exclusivity and how do dates map to generic launches?

Answer: Exclusivity loss dates cannot be provided without validated Orange Book and FDA exclusivity records for GENAPAX.

Which companies compete with GENAPAX in antiemetic supportive care?

Answer: GENAPAX’s competitive set is defined by other CINV antiemetics used in oncology supportive-care workflows, typically including:

• 5-HT3 receptor antagonists
• NK1 receptor antagonists
• Corticosteroids (as part of combination regimens)
• Dopamine antagonists
• Other supportive antiemetics used for breakthrough or regimen-specific prophylaxis

A precise competitor roster with market-share attribution requires a validated brand and label mapping to FDA-approved comparators, which is not available in the current input.

How does GENAPAX compare with other antiemetics on market access and payer coverage?

Answer: In mature supportive-care classes, payers favor agents that combine guideline-aligned efficacy with predictable acquisition cost and formulary interchangeability.

Commercial comparison axes:

• Step-therapy usage rules in managed care
• Preferred drug lists for emetogenic risk tiers
• Institutional contract pricing and pharmacy committee preferences
• Administration convenience and supply reliability

What FDA regulatory events affect GENAPAX’s market trajectory?

Answer: Regulatory events that materially affect GENAPAX market trajectory generally include label updates, manufacturing changes that impact supply, and any FDA communications affecting availability or distribution.

A complete regulatory timeline requires validated FDA action records for GENAPAX.

What patent litigation affects GENAPAX or its generics?

Answer: Patent litigation impacts are not quantifiable here without a list of relevant Paragraph IV actions, district court filings, PTAB outcomes, or settlement terms tied to GENAPAX’s Orange Book patents.

What settlement agreements could delay generic entry for GENAPAX?

Answer: Settlement agreements cannot be listed without an evidence-backed docket of relevant litigations and negotiated terms.

How many formulation and method-of-use patents protect GENAPAX dosing and product availability?

Answer: A reliable count of formulation and method-of-use patents requires an Orange Book-linked claim set and patent family mapping for GENAPAX, which is not available in the current material.

What commercial performance metrics best describe GENAPAX’s financial trajectory?

Answer: For mature antiemetics like GENAPAX, the most decision-grade metrics are:

• U.S. net sales trend (quarterly and annual)
• Gross-to-net, rebate pressure, and payer contract outcomes
• Market share by formulary tier (preferred vs non-preferred)
• Channel mix: hospital vs retail vs specialty distribution
• Inventory and supply stability, which can create temporary sales dips or surges

These metrics require company financial disclosures or audited sales datasets.

Revenue exposure: where GENAPAX is vulnerable to substitution and price compression

Answer: Revenue exposure concentrates in:

• Institutions that can switch within antiemetic order sets without clinical friction
• Payor plans that push step edits or prefer lower-acquisition-cost alternatives
• Formularies where procurement renegotiates pricing as contracts expire

Key Takeaways

• GENAPAX demand is anchored in mature oncology supportive-care CINV workflows, where growth is limited and substitution pressure is persistent.
• Market dynamics are driven by formulary standardization, protocol evolution, and contracting economics rather than new clinical adoption.
• Financial trajectory should be characterized as low-growth to declining absent new label differentiation, with revenue compression risk from alternatives and generic substitution.
• Patent and exclusivity-driven competitive timing cannot be mapped accurately without a validated Orange Book and FDA exclusivity dataset for GENAPAX.

FAQs

1. How do antiemetic guideline updates typically change market share for older CINV brands like GENAPAX?
2. What pricing levers (rebates, rebates clawbacks, ASP vs contract pricing) most influence net sales for mature antiemetics?
3. How do hospital formulary committees decide between competing CINV regimens that include 5-HT3 and NK1 components?
4. What indicators in FDA data signal supply disruptions that can temporarily distort GENAPAX sales?
5. How can patent claim narrowing or label carve-outs reduce generic threat even after primary exclusivity ends?

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (search for GENAPAX entries). U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and label information for GENAPAX. U.S. Food and Drug Administration.